NCT00733304 - An Extension to Study MD7108240 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 25, 2008

Primary Completion Date

September 9, 2009

Study Completion Date

September 9, 2009

Conditions

Macular Degeneration

Interventions

DRUG

Pazopanib

5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD

Trial Locations (17)

2145

GSK Investigational Site, Sydney

2150

GSK Investigational Site, Sydney

6009

GSK Investigational Site, Perth

10122

GSK Investigational Site, Turin

20132

GSK Investigational Site, Milan

20157

GSK Investigational Site, Milan

33880

GSK Investigational Site, Winter Haven

35128

GSK Investigational Site, Padua

46280

GSK Investigational Site, Indianapolis

48105

GSK Investigational Site, Ann Arbor

49525

GSK Investigational Site, Grand Rapids

50134

GSK Investigational Site, Florence

84132

GSK Investigational Site, Salt Lake City

90211

GSK Investigational Site, Beverly Hills

95841

GSK Investigational Site, Sacramento

02111

GSK Investigational Site, Boston

Unknown

GSK Investigational Site, Melbourne